scPharmaceuticals Inc SCPH
News
scPharmaceuticals Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
scPharmaceuticals Announces Pricing of $50.0 Million Public Offering
scPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $125 Million with Perceptive Advisors
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart Failure
scPharmaceuticals Announces Positive Topline Study Results for SCP-111 (Furosemide 80 mg/1 mL) Autoinjector
scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
scPharmaceuticals to Announce Second Quarter 2024 Financial Results on Wednesday, August 14, 2024
scPharmaceuticals Announces Filing Acceptance of Supplemental New Drug Application (sNDA) Seeking to Expand FUROSCIX Indication to Include Chronic Kidney Disease